The Pill That Kills Quietly: What Every Brother Should Know About Chemical Abortion (Part 2)
By Ray Ross (Respect Life Team)
Last month I covered how the abortion pill works and what risks women face who take the abortion pill. In this article I’ll cover recent Senate Hearings as well as actions by the Courts.
The Senate Hearing: "Can Men Get Pregnant?"
On January 14, 2026, the Senate Health, Education, Labor, and Pensions Committee — chaired by physician-senator Bill Cassidy (R-La.) — held its first pro-life-oriented hearing of the new Congress, titled "Protecting Women: Exposing the Dangers of Chemical Abortion Drugs." Cassidy opened by arguing that a child's worth doesn't change based on whether she's in her mother's arms or still in the womb, and he pressed the FDA to finally complete the mifepristone safety review insisting that, at minimum, the old in-person dispensing rule be restored right away.
Two witnesses anchored the pro-life case. Louisiana Attorney General Liz Murrill testified about women and girls she said had been coerced or secretly drugged with abortion pills — cases her office has since prosecuted under state law. Dr. Monique Chireau Wubbenhorst, a board-certified OB-GYN and senior fellow at Notre Dame's de Nicola Center for Ethics and Culture, walked the committee through the clinical risks of the regimen — bleeding, infection, hemorrhage, and the potential need for a blood transfusion — and warned that taking the drugs while unaware of an ectopic pregnancy can be life-threatening. She told senators the lack of in-person screening has turned the pills into a tool of abuse, describing documented cases of partners secretly slipping the drug into food or drinks, or forcing women to take it against their will.
The hearing's most viral moment came when Sen. Josh Hawley (R-Mo.) turned to the Democrats' witness, OB-GYN Dr. Nisha Verma of Physicians for Reproductive Health, and asked her point-blank whether men can get pregnant. Verma declined to answer with a simple yes or no, saying she didn't want the question weaponized. Hawley pressed the point repeatedly, then tied it back to the hearing's purpose: the committee was examining the safety of a drug taken exclusively by women, he said, and a witness unwilling to affirm that basic biological fact raised doubts about whether politics was distorting the broader medical defense of the pill.
Hawley followed the hearing with legislative action, introducing the Safeguarding Women from Chemical Abortion Act in March 2026, which would revoke the FDA's approval of mifepristone outright.
The Supreme Court, Round Two
The legal fight over these pills didn't end with the Supreme Court's 2024 ruling that pro-life doctors lacked standing to challenge the FDA's approval of mifepristone. It simply moved to a plaintiff with a stronger claim: the state of Louisiana.
Louisiana sued the FDA directly, arguing that the agency's 2021 and 2023 decisions allowing mifepristone to be prescribed via tele-health and mailed to patients — without any in-person visit — undermined the state's own near-total abortion ban, since out-of-state doctors can simply mail the pills across Louisiana's border. By one count cited in the litigation, mifepristone shipped into Louisiana enables nearly a thousand abortions a month despite the state's law.
In a dramatic sequence in early May 2026, a three-judge panel of the Fifth Circuit Court of Appeals — composed entirely of Republican appointees — sided with Louisiana and ordered the in-person dispensing rule reinstated nationwide, not just within the state. The order would have immediately required women anywhere in the country to see a doctor in person before receiving the drug. The manufacturers, Danco Laboratories and GenBioPro, raced to the Supreme Court, and Justice Samuel Alito issued a series of short-term stays while the full Court deliberated. On May 14, 2026, the Court sided with the manufacturers, preserving the mail-order status quo while Louisiana's case proceeds at the Fifth Circuit. Justices Thomas and Alito dissented; Thomas argued separately that shipping mifepristone for use in an abortion is already a federal crime — a reference to the long-dormant 1873 Comstock Act, which bars mailing anything intended to produce an abortion, and which pro-life litigators are increasingly urging the courts and the Trump administration to enforce.
The case is not over. It now returns to the Fifth Circuit for a full hearing on the merits and could land back at the Supreme Court for a final ruling within the next year or two.
The Race to Get Around Restrictions
While Congress and the courts argue over paperwork, the practical battle has already moved underground, into a patchwork of state shield laws and cross-border tele-health networks that pro-life advocates say render existing abortion bans nearly meaningless.
Twenty-two states and Washington, D.C. now have "shield laws" protecting abortion providers from out-of-state prosecution, and eight of those states explicitly extend that protection to clinicians who mail abortion pills to patients living under total bans elsewhere. Louisiana became the first state to test this system criminally, indicting a New York physician for allegedly mailing pills to a pregnant Louisiana teenager — but New York, invoking its own shield law, has refused to extradite the doctor. Texas has filed similar civil suits against out-of-state providers, including the Netherlands-based tele-health group Aid Access, which by its founder's own account now sends pills to thousands of American women a month regardless of their home state's law.
The pharmaceutical industry has been just as aggressive in defending the current system, with Danco and GenBioPro filing emergency briefs at every level of the federal courts to keep tele-health access intact.
What This Means
The pattern here should trouble anyone who cares about women's safety: a drug regimen whose real-world complication rate is now seriously disputed, dispensed increasingly without a doctor ever laying eyes on the patient, shipped across state lines specifically to defeat the laws of the states that have banned it, and defended in court primarily by the companies that profit from its sale.
For pro-life supporters, the task in the meantime is clear: keep making the case, plainly and honestly, that a woman deserves to see a doctor, not just a website, before she takes a drug that will end her child's life and carries real risks to her own.